ArticleProceedings of the National Academy of Sciences of the United States of America2003
Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 64 citations in OpenAlex.
- Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.Frontiers in immunology · 2023Review
- CAR-T cell potency: from structural elements to vector backbone components.Biomarker research · 2022Review
- The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity.Frontiers in immunology · 2020Review
- Immunology of Adenoviral Vectors in Cancer Therapy.Molecular therapy. Methods & clinical development · 2019Review
- Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Immunotherapy · 2017Review
- CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.Oncoimmunology · 2016Review
- Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.Journal of immunology research · 2016Review
- CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.Immunology and cell biology · 2013Article
- The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis.Journal of biomedicine & biotechnology · 2012Review
- 4-1BB signaling breaks the tolerance of maternal CD8+ T cells that are reactive with alloantigens.PloS one · 2012Article
- 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Article
- The oxazolidinone derivative locostatin induces cytokine appeasement.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo.Journal of leukocyte biology · 2009Article
- The role of TNF superfamily members in T-cell function and diseases.Nature reviews. Immunology · 2009Review
- Integrating costimulatory agonists to optimize immune-based cancer therapies.Immunotherapy · 2009Review
- Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.International journal of hematology · 2007Article
- CD8+ T cell dysfunction and increase in murine gammaherpesvirus latent viral burden in the absence of 4-1BB ligand.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
- Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
To better understand how innate and adaptive immune responses interact with each other, we combined 4-1BB T cell costimulation with specific adjuvants to determine whether these treatments would influence specific T cell expansion and function in vivo. In the presence of 4-1BB ligation and Toll-like receptor 3 (TLR)3 and/or TLR4 triggering, CD8 T cell clonal expansion and survival was augmented profoundly. Specific T cells primed in vivo with TLR ligands responded normally to in vitro recall stimulus, but, surprisingly, copriming with 4-1BB costimulation significantly impaired the recall response even though many more specific effector T cells were rescued in vivo. Here, we demonstrate that the rescued CD8 T cells suppressed CD4 T cell proliferation via a type beta transforming growth factor-dependent mechanism. Thus, 4-1BB and TLR ligands induce survival of specific effector CD8 T cells with suppressive recall potential, which may explain the dual role that 4-1BB activation plays in mediating tumor clearance and prevention of autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.